Tokyo, Apr 6, 2009 (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai entered into a license agreement with Nobelpharma Co., Ltd. in which Eisai gives Norbelpharma the exclusive right to develop and commercialise GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) in Japan, while retaining an option right to obtain the exclusive commercialisation right of GLIADEL Wafer in Japan once the NDA has been filed for approval.
